EGF-L7 human

NA.32

EGF-L7 (Epidermal Growth Factor Like Protein 7, Multiple EGF Like Domains Protein 7, VE Statin) is a multi-domain protein containing two EGF like domains and one EMI domain. It is expressed almost exclusively in endothelial cells and functions to promote normal development of the vascular system, particularly tubulogenesis. EGF-L7 is capable of antagonistic binding to Notch receptors resulting in the inhibition of Notch signaling in HUVEC and neural stem cells. In research models inducing hypoxia and subsequent reoxygenation, (H/R), EGF-L7 can inhibit ICAM-1 expression and enhance the inhibition of NF-kappaB activation. Additionally, EGF-L7 can chemoattract endothelial cells and bind to the extracellular matrix. The overexpression of EGF-L7 is observed in various cancers, and is generally correlated with increased metastasis and a poor prognosis. Recombinant human EGF-L7 is a 28 kDa protein containing 251 amino acid residues.

EGF-L7 (Epidermal Growth Factor Like Protein 7, Multiple EGF Like Domains Protein 7, VE Statin) is a multi-domain protein containing two EGF like domains and one EMI domain. Recombinant human EGF-L7 is a 28 kDa protein containing 251 amino acid residues.

Lyophilized with no additives.

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8℃ for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20℃ to -80℃.

human

expressed in E. coli

≥98% (HPLC)
≥98% (SDS-PAGE or HPLC)

lyophilized

28.0 kDa

pkg of 10 μg

endotoxin, tested

Q9UHF1

wet ice

−20℃

human ... EGFL7(51162)

13 - Non Combustible Solids

WGK 3